The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome.

dc.contributor.authorVidal, Silvia
dc.contributor.authorBrandi, Núria
dc.contributor.authorPacheco, Paola
dc.contributor.authorGerotina, Edgar
dc.contributor.authorBlasco, Laura
dc.contributor.authorTrotta, Jean-Rémi
dc.contributor.authorDerdak, Sophia
dc.contributor.authorDel Mar O'Callaghan, Maria
dc.contributor.authorGarcia-Cazorla, Àngels
dc.contributor.authorPineda, Mercè
dc.contributor.authorArmstrong, Judith
dc.contributor.authorRett Working Group
dc.date.accessioned2025-01-07T13:23:05Z
dc.date.available2025-01-07T13:23:05Z
dc.date.issued2017-09-25
dc.description.abstractRett syndrome (RTT) is an early-onset neurodevelopmental disorder that almost exclusively affects girls and is totally disabling. Three genes have been identified that cause RTT: MECP2, CDKL5 and FOXG1. However, the etiology of some of RTT patients still remains unknown. Recently, next generation sequencing (NGS) has promoted genetic diagnoses because of the quickness and affordability of the method. To evaluate the usefulness of NGS in genetic diagnosis, we present the genetic study of RTT-like patients using different techniques based on this technology. We studied 1577 patients with RTT-like clinical diagnoses and reviewed patients who were previously studied and thought to have RTT genes by Sanger sequencing. Genetically, 477 of 1577 patients with a RTT-like suspicion have been diagnosed. Positive results were found in 30% by Sanger sequencing, 23% with a custom panel, 24% with a commercial panel and 32% with whole exome sequencing. A genetic study using NGS allows the study of a larger number of genes associated with RTT-like symptoms simultaneously, providing genetic study of a wider group of patients as well as significantly reducing the response time and cost of the study.
dc.identifier.doi10.1038/s41598-017-11620-3
dc.identifier.essn2045-2322
dc.identifier.pmcPMC5613000
dc.identifier.pmid28947817
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5613000/pdf
dc.identifier.unpaywallURLhttps://www.nature.com/articles/s41598-017-11620-3.pdf
dc.identifier.urihttps://hdl.handle.net/10668/25468
dc.issue.number1
dc.journal.titleScientific reports
dc.journal.titleabbreviationSci Rep
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.number12288
dc.pubmedtypeEvaluation Study
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshCohort Studies
dc.subject.meshDNA Copy Number Variations
dc.subject.meshForkhead Transcription Factors
dc.subject.meshGenetic Testing
dc.subject.meshHigh-Throughput Nucleotide Sequencing
dc.subject.meshHumans
dc.subject.meshMethyl-CpG-Binding Protein 2
dc.subject.meshMutation
dc.subject.meshNerve Tissue Proteins
dc.subject.meshPolymorphism, Single Nucleotide
dc.subject.meshProtein Serine-Threonine Kinases
dc.subject.meshRett Syndrome
dc.subject.meshExome Sequencing
dc.titleThe utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number7

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC5613000.pdf
Size:
1.2 MB
Format:
Adobe Portable Document Format